The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median survival of 27 months versus 11.2 months with standard treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07490301 |
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07475234 |
Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07445295 |
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07214298 |
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07165951 |
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
RECRUITING | PHASE3 |
| NCT07096362 |
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma |
RECRUITING | PHASE2 |
| NCT07089940 |
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
RECRUITING | EARLY_PHASE1 |
| NCT06989437 |
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue |
RECRUITING | PHASE2/PHASE3 |
| NCT06981806 |
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT06917079 |
BBO-11818 in Adult Subjects With KRAS Mutant Cancer |
RECRUITING | PHASE1 |
